Drug Profile

VIR 201

Alternative Names: Co-X-Gene HIV vaccine; VIR201

Latest Information Update: 24 Sep 2015

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Virax Holdings
Developer Australian National University; Prescient Therapeutics
Class AIDS vaccines
Mechanism of Action Immunomodulators; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued HIV-1 infections

Most Recent Events

19 Jul 2007 Clinical data added to the adverse events and Viral Infections immunogenicity sections ,,
21 Nov 2006 The US FDA has approved the IND application for a phase II trial of VIR 201 in the US
25 Oct 2006 Virax has filed an IND with the FDA in the United States for HIV Infections

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com